Sihuan raises $715 million in Hong Kong listing
This article was originally published in Scrip
Sihuan Pharmaceutical Holdings Group, the Chinese cardio- and cerebrovascular pharmaceuticals company, raised HK$5.5 billion ($715 million) in an IPO on the Hong Kong Stock Exchange. The company offered 1.25 billion shares at HK$4.60 each and was heavily over-subscribed.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.